Search results
Results from the WOW.Com Content Network
2C-B (4-bromo-2,5-dimethoxyphenethylamine), also known as Nexus, is a synthetic psychedelic drug of the 2C family, mainly used as a recreational drug. [2] [1] [4] It was first synthesized by Alexander Shulgin in 1974 for use in psychotherapy.
The cannabinoid receptor 2 (CB2), is a G protein-coupled receptor from the cannabinoid receptor family that in humans is encoded by the CNR2 gene. [5] [6] It is closely related to the cannabinoid receptor 1 (CB1), which is largely responsible for the efficacy of endocannabinoid-mediated presynaptic-inhibition, the psychoactive properties of tetrahydrocannabinol (THC), the active agent in ...
While found only in the peripheral nervous system, a report does indicate that CB 2 is expressed by a subpopulation of microglia in the human cerebellum. [20] CB 2 receptors appear to be responsible for immunomodulatory [19] and possibly other therapeutic effects of cannabinoid as seen in vitro and in animal models. [18]
Tactogen is additionally studying a combination of MDMA and citalopram wherein MDMA is followed by the selective serotonin reuptake inhibitor (SSRI) citalopram in efforts to reduce the serotonergic neurotoxicity and negative after-effects of MDMA. [7] [25] [23] [26] A phase 2 trial of this strategy is planned to commence in 2025.
These effects are common for most psychedelics in the substituted phenethylamine class. There is a strong similarity between the subjective effects caused by βk-2C-B and 2C-B. However, βk-2C-B is often described to be more stimulating and less psychedelic. This, combined with its long duration, could increase the perceived severity of the ...
A dried cannabis flower. The short-term effects of cannabis are caused by many chemical compounds in the cannabis plant, including 113 [clarification needed] different cannabinoids, such as tetrahydrocannabinol, and 120 terpenes, [1] which allow its drug to have various psychological and physiological effects on the human body.
25B-NBOMe (NBOMe-2C-B, Cimbi-36, Nova, BOM 2-CB) is a derivative of the phenethylamine psychedelic 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent full agonist for the 5HT 2A receptor .
There are two known subtypes of cannabinoid receptors, termed CB 1 and CB 2. [6] [7] The CB 1 receptor is expressed mainly in the brain (central nervous system or "CNS"), but also in the lungs, liver and kidneys. The CB 2 receptor is expressed mainly in the immune system, in hematopoietic cells, [8] and in parts of the brain. [9] The protein ...